TrialCompass™ TCL
Back to results
RecruitingPriority 3 · Moderate priorityNCT03932279

Characterization of the Microbiome in Cutaneous T Cell Lymphoma

ClinicalTrials.gov

Plain-language summary

This study is studying a new treatment for people with anaplastic large cell lymphoma (ALCL). The study measures how well this treatment works and monitors for side effects. It is available at 1 US location.

Who can join (key eligibility)

  • Age 18 Years to 89 Years years
  • See full trial listing for complete eligibility

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

Drugs / treatments
Treatment length
Ask the trial team for details
Visit frequency
Ask the trial team for details
TrialCompass — Clinical Trial Summary

Characterization of the Microbiome in Cutaneous T Cell Lymphoma

NCT03932279

Status: Recruiting | Priority: Medium

Plain-language summary

This study is studying a new treatment for people with anaplastic large cell lymphoma (ALCL). The study measures how well this treatment works and monitors for side effects. It is available at 1 US location.

Who can join

  • Age 18 Years to 89 Years years
  • See full trial listing for complete eligibility

What's being tested

Drugs / treatments:

Treatment length: Ask the trial team for details

Visit frequency: Ask the trial team for details

Trial design

Non-randomized, blind

Enrollment target: 300 patients

Primary endpoint: Bacterial diversity index

Ages: 18 Years to 89 Years

Start date: 2019-01-30 | Est. completion: 2028-08-31

Locations

1 US sites · 1 total

Illinois

Contact

Dermatology CTU | NUderm-research@northwestern.edu | 312-503-5944

Sponsor: Northwestern University (OTHER)

Tags

ALCL · any

View on ClinicalTrials.gov

https://clinicaltrials.gov/study/NCT03932279

Prepared using TrialCompass (trialcompass.com) on July 4, 2026. For informational purposes only. Always discuss with your healthcare team.